Expert: Adeno-associated virus vector delivering anti-VEGF transgene for sustained intraocular expression, reducing need for repeated intravitreal injections.

Everyday: A one-time gene therapy that helps the eye produce its own anti-VEGF protein to treat vision loss.

Targets: ["VEGF"]

ABBV-RGX-314 - Wet AMD - Ph3 - Data (ATMOSPHERE) 2026-2027

AAV gene therapy for wet AMD. Delivers anti-VEGF gene for durable expression. Potential one-time treatment alternative to chronic anti-VEGF injections.